

# OXURION N.V.

ISIN: BE0003846632 WKN: - Asset Class: **Stock**

## Company


2024/07/08 10:31:07

OXURION®

Price

0.00 EUR

Difference ▲ 0.00%(0.00)



## Contact Details

OXURION NV

Tel: +32-1-675-13-10

--

Fax: +

Gaston Geenslaan 1, Heverlee

Web: <http://www.oxurion.com>

3001 Leuven

E-mail: [info@oxurion.com](mailto:info@oxurion.com)

## Company Profile

Oxurion NV is a biopharmaceutical company, which engages in developing and commercializing medicines for the treatment of vitreo retinal diseases. It operates under JETREA brand name. The company was founded by Desire Collen in 1991 and is headquartered in Leuven, Belgium.

## Financial figures, Fiscal year: from 01.01. to 31.12.

Financial figures	2023		2022		2021	
	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
Current assets	2,740,000		7,106,000		13,409,000	
Common stock capital		72,993,000		65,443,000		46,029,000
Fixed assets	3,810,000		4,887,000		5,467,000	
Equity capital of a company		-13,186,000		-4,583,000		-1,108,000
Cash and cash equivalents	1,624,000		3,496,000		9,740,000	
Accrued liabilities		12,000		159,000		594,000
Other assets	-		-		-	
Current liabilities		19,607,000		12,349,000		10,913,000
Prepayments and accrued income	-		-		-	
Non-current liabilities		129,000		4,227,000		9,071,000
Different income		-		-		-
Other liabilities		0		0		0
Total assets	6,550,000	6,550,000	11,993,000	11,993,000	18,876,000	18,876,000

## Balance notes

	2023	2022	2021
Accounting standard	IFRS	IFRS	IFRS
Employees	19	27	42
Equity ratio	-201.31%	-38.21%	-6.03%
Debt-equity ratio	-149.67%	-361.68%	-1,758.70%

## Others

	2023	2022	2021
Tax Expense Rate	-0.02%	-0.02%	-0.01%

**Income statement**

	<b>2023</b>	<b>2022</b>	<b>2021</b>
<b>Turnover</b>	263,000	595,000	1,128,000
<b>Net income</b>	-18,969,000	-31,685,000	-29,158,000
<b>EBIT</b>	-16,999,000	-30,325,000	-28,862,000
<b>Operating income before taxes</b>	-18,966,000	-31,686,000	-29,592,000
<b>Cash Flow</b>	-10,080,000	-20,016,000	-27,155,000
<b>Net interest income</b>	-1,967,000	-1,361,000	-730,000
<b>Research and development expenses</b>	9,754,000	15,684,000	20,196,000
<b>Income taxes</b>	3,000	7,000	3,000
<b>Result from investments in subsidiaries, associates and other</b>	0	0	0
<b>Revenues per employee</b>	13,842	22,037	26,857

**Board of Directors**

Charles Paris de Bollardire	Chairman of Supervisory Board
Anat Loewenstein	Member of Supervisory Board
James Hartmann	Member of Supervisory Board
Nathalie Laarakker	Member of Supervisory Board

**Members of Management Board**

Tom Graney	Chairman of Managing Board
Andy De Deene	Member of Executive Committee
Kathleen Paisley	Member of Executive Committee
Michael Dillen	Member of Executive Committee